Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.
|Videos|July 3, 2018
Overcoming Barriers and Stigma as a Young Patient
Author(s)Taylor Bell Duck
Taylor Bell Duck was only 21 when she was diagnosed with lung cancer, a disease that is often stigmatized.
Advertisement
Taylor Bell Duck was only 21 when she was diagnosed with lung cancer, a disease that is often stigmatized.
But being a young, never-smoker diagnosed seemingly out of the blue was not the only issue that Duck faced. Getting cancer in young adulthood also can bring significant financial burden, too.
Music: bensound.com
Advertisement
Related to this article
In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.
Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.
The FDA withdrew Zepzelca’s accelerated approval for small cell lung cancer after the LAGOON trial failed to show longer survival. Its maintenance use with Tecentriq is unaffected.
In the phase 3 MAVERICK trial, people with small cell lung cancer who had regular brain MRIs instead of preventive whole-brain radiation kept their memory and thinking intact longer, with no clear survival difference so far.
The FDA has granted two Breakthrough Therapy Designations to AbbVie's investigational drug Temab-A, one for use in metastatic colorectal cancer and one for non-small cell lung cancer, based on early-phase trial data.
A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.
A phase 3 trial found that adding Imdelltra to Imfinzi maintenance improved survival in extensive-stage small cell lung cancer, while another drug's application was pulled. Here's what patients should know.
Advertisement
Advertisement
Trending on CURE
1
Why PSA Monitoring Matters After a Prostate Cancer Diagnosis
2
FDA Withdraws Zepzelca Approval for Previously Treated Small Cell Lung Cancer
3
Life After Cancer: Challenge Yourself to Build Healthier Habits and Stronger Relationships
4
Rina-S Shows 45.9% Response Rate in Platinum-Resistant Ovarian Cancer
5